Sponsored

Prescient’s (ASX: PTX) abstract for PTX-100 features on ASH website

November 06, 2023 12:50 PM IST | By Sonal Goyal

Highlights

  • Prescient Therapeutics’ abstract for PTX-100 has been published on the American Society of Hematology (ASH) website
  • PTX-100 Phase 1b study is ongoing with patients with refractory and relapsed TCL
  • The trial results are anticipated to be released on the ASX in December 2023

Prescient Therapeutics Limited (ASX: PTX) informed that its PTX-100’s abstract has been published on the American Society of Hematology (AXH) website before the scheduled presentation on 9 December 2023.

The abstract concerns the interim results from the ongoing Phase 1b study examining PTX-100 in patients with relapsed and refractory T-cell lymphoma (TCL).

Data source: Company update

The abstract highlights that as at the cut-off date, total 14 patients were treated, of which 10 patients underwent response assessment after four-cycle therapy and the overall response rate was 40%. For the abstract, data cut off was 10 July 2023 and the study is going on.

Data source: Company update

The results of the PTX-100 Phase 1b trial that comprises additional and updated data are likely to be announced in December 2023, after the ASH presentation.

PTX shares traded at AU$0.056 apiece at the time of writing on 6 November 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.